Skip to main content
Premium Trial:

Request an Annual Quote

Era7 Joins Global Genomics Alliance

NEW YORK (GenomeWeb) – Era7 Bioinformatics said today it is now a member of the Global Alliance for Genomics and Health, an international coalition formed to facilitate worldwide sharing of genomic and clinical data.

Era7's CEO Eduardo Pareja said in a statement that his firm is committed to collaborating with other alliance members to reach the group's stated objectives and to "support advances in human health through scientific collaboration."

Era7 provides services around open source software that it has developed to help clients annotate and compare genomic and transcriptomic data from bacteria and metagenomes. It also offers a cancer genome analysis service dubbed Genome7 that is based on Bio4j, an internally developed graph-based data framework for protein-related querying and management. Bio4j was one of the projects selected for this year's Google Summer of Code, an annual program that offers students a chance to contribute code to open source projects over the summer.

Era7 is headquartered in Madrid and it has a subsidiary in Cambridge, Mass.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.